10-Q · May 15, 2026
Dogwood Therapeutics reported improved Q1 2026 results with a significant reduction in net loss to $5.0 million (-$0.15 EPS) from a loss of $12.2 million (-$8.45 EPS) in the prior year, but with no generated revenue,…
Earnings analysis · 10-Q
DWTX earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
Dogwood reported no revenue and a diluted EPS loss of $0.34, with results pressured by a $6.7 million net non-cash impairment charge and higher operating expenses. The company had $9.6 million of cash and stated that it…
Read full summary
Dogwood reported no revenue and a diluted EPS loss of $0.34, with results pressured by a $6.7 million net non-cash impairment charge and higher operating expenses. The company had $9.6 million of cash and stated that it provides runway through Q4 2026, while Halneuron Phase 2b results remain expected in fall 2026. The 10-Q provides no formal numeric guidance and reports no material changes to the risk factors from the 2025 Form 10-K.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.34
What stood out
-
No Revenue; $0.34 EPS Loss
Revenue was $0 and diluted EPS was a loss of $0.34 for the quarter, continuing the company’s pre-commercial profile and producing a weaker result than the prior quarter’s $0.15 loss.
-
Cash Runway Through Q4 2026
Cash and cash equivalents were $9.6 million, which management said provides runway through Q4 2026.
-
Phase 2b Readout on Track
Management said Halneuron Phase 2b top-line results remain on track for fall 2026, providing the principal near-term clinical catalyst.
-
Controls Remained Effective
Management concluded that disclosure controls were effective as of the end of the period, and reported no changes in internal control that materially affected or were reasonably likely to materially affect controls during the quarter.
What to watch
-
Material Impairment Charge
The quarter included a $6.7 million net non-cash impairment charge, which contributed to the $0.34 diluted EPS loss and signals pressure on the value of underlying assets.
-
Pre-Revenue Losses Continue
The company reported $0 revenue and a $0.34 diluted EPS loss, while higher operating expenses continued to pressure results in the absence of commercial revenue.
-
Limited Liquidity Runway
The $9.6 million cash balance is expected to fund operations only through Q4 2026, leaving limited liquidity beyond the planned Halneuron Phase 2b readout.
-
Clinical Readout Risk
The principal near-term value driver remains the Halneuron Phase 2b top-line readout expected in fall 2026; unfavorable results could materially affect the company’s outlook.
-
No New Risk-Factor Changes
The 10-Q states there were no material changes from the risk factors in the 2025 Annual Report on Form 10-K; therefore, no new risk-factor update was identified in this filing.
Management's outlook
No formal quantitative revenue or EPS guidance was provided. Management expects Halneuron Phase 2b top-line results in fall 2026 and stated that the $9.6 million cash balance provides runway through Q4 2026.
Earlier filings 4
10-K · March 18, 2026
Dogwood Therapeutics is a pre-revenue, development‑stage biotech focused on Halneuron® (Nav1.7 TTX analgesic) and SP16 (serpin peptide) for neuropathic pain. The 10‑K highlights encouraging clinical signals…
10-Q · November 7, 2025
Dogwood reported a sharply wider Q3 2025 net loss of $15,744,616 (EPS -$8.20) versus a loss of $2,280,684 (EPS -$2.05) in Q3 2024, driven by a large increase in R&D and a $12,030,667 non‑cash license acquisition charge.…
10-Q · August 13, 2025
Dogwood Therapeutics reported a Q2 net loss of $3,807,353 (EPS -$1.99), a larger loss than the $1,049,833 loss (EPS -$1.15) in Q2 2024, driven by a step-up in R&D and G&A. Cash totaled $13,402,809 at June 30, 2025 (up…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.